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The number of different assays that has been published to study DNA methylation is extensive, complemented by
recently described assays that test modifications of cytosine other than the most abundant 5-methylcytosine (5mC)
variant. In this review, we describe the considerations involved in choosing how to study 5mC throughout the
genome, with an emphasis on the common application of testing for epigenetic dysregulation in human disease.
While microarray studies of 5mC continue to be commonly used, these lack the additional qualitative information
from sequencing-based approaches that is increasingly recognized to be valuable. When we test the representation
of functional elements in the human genome by several current assay types, we find that no survey approach
interrogates anything more than a small minority of the nonpromoter cis-regulatory sites where DNA methylation
variability is now appreciated to influence gene expression and to be associated with human disease. However,
whole-genome bisulphite sequencing (WGBS) adds a substantial representation of loci at which DNA methylation
changes are unlikely to be occurring with transcriptional consequences. Our assessment is that the most effective
approach to DNA methylation studies in human diseases is to use targeted bisulphite sequencing of the cis-regulatory
loci in a cell type of interest, using a capture-based or comparable system, and that no single design of a survey
approach will be suitable for all cell types.
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While it is customary to think of DNA as containing
four nucleotides - adenine, thymine, guanine and cyto-
sine - the cytosines in many organisms represent targets
for several covalent modifications, now recognized to in-
clude 5-methylcytosine (5mC), 5-hydroxymethylcytosine
(5hmC), 5-carboxylcytosine (5caC) and 5-formylcytosine
(5fC) (reviewed in [1]). Of these, 5mC is the most abun-
dant alternative version of cytosine [2]. The cytosine
5mC was first recognized as a toxic extract from Myco-
bacterium tuberculi in 1898 and named tuberculinic acid
as a result [3]. Studies of neoplastic cells in the 1980s
revealed differences in 5mC content compared with
nontransformed cells [4,5], opening up the possibility
that studies of human development and diseases, in-
cluding cancer in particular, may involve this nucleotide
variant [6].* Correspondence: john.greally@einstein.yu.edu
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article, unless otherwise stated.The decades since have seen a steady progression in
our capability to study 5mC more broadly throughout
the genome, at increasing resolution and in an expand-
ing range of organisms. Some of the earliest approaches
involved performing Southern blots using DNA pre-
digested with restriction enzymes that are sensitive to
the presence of 5mC [7]. This approach allowed some of
the earliest observations of cancer-related 5mC changes
[4] and revealed the role of 5mC in developmental regu-
lation of gene expression due to genomic imprinting in
mammals [8]. The development of the polymerase chain
reaction (PCR) led to new assays being designed, with
some based on ligation-mediated PCR [9] and others on
the amplification across the sites that could be digested
by a specific restriction enzyme [10]. The latter type of
assay enabled the sensitive detection of the presence of
methylated DNA at loci where 5mC was normally com-
pletely absent, which became a major means of testing
for the presence of abnormal DNA methylation in can-
cer in particular [11,12].d Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Cytosine variants and their production. We show how
cytosine within DNA can be acted upon by DNA methyltransferases
(DNMT) to generate 5-methylcytosine (5mC), which can subsequently
be oxidized by TET enzymes through the 5-hydroxymethylation
(5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) variants,
favoring the activity of thymine DNA glycosylase to create an abasic
site that can then be repaired to add back an unmethylated cytosine
to complement the guanine on the other strand. As well as alpha-
ketoglutarate (α-KG), another known TET enzyme cofactor is ascorbic
acid (vitamin C).
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ure DNA methylation was the development of bisulphite
conversion, which was found to deaminate selectively cy-
tosines but not 5mC [13]. Once converted, downstream
assays could be applied, including not only restriction
enzyme digestion but also currently-available sequencing-
based approaches. The restriction enzyme-based approa-
ches included COBRA (COmbined Bisulphite Restriction
Analysis [14]), which generally exploited the destruction
by bisulphite exposure of a pre-existing restriction enzyme
site or the creation of a new one. However, for the first
time, DNA sequencing could be applied to the product of
the bisulphite treatment, generally involving PCR of the
bisulphite-treated DNA followed by sequencing [13]. This
generates nucleotide-resolution quantification of DNA
methylation, while cloning and sequencing of the PCR
product add allelic information, shedding further light
upon processes like genomic imprinting [15]. Other
technologies were also applied downstream of bisul-
phite treatment, including pyrosequencing [16] and mass
spectrometry [17], which were designed to enable more
accurate quantification of 5mC at sites within the ampli-
cons tested.
The development of massively-parallel sequencing
(MPS) in the last decade has allowed the product of
bisulphite conversion to be sequenced on a scale never
previously possible. During the MPS era, it has emerged
that 5mC is not the only cytosine variant in the genome,
but is accompanied by lower proportions of 5hmC [2],
5caC and 5fC [18] (Figure 1). It became apparent that
previous assays involving bisulphite conversion read each
of these cytosine modifications differently [19] (Figure 2),
which prompted the need to re-evaluate prior assump-
tions about distributions of modified cytosines in the gen-
ome. Assay development for these new modifications is
focused on exploiting MPS technologies, resulting in some
intriguing early observations about the distributions of
some of these cytosine variants. For example, 5hmC
can be tested using Tet-assisted bisulphite sequencing
(TAB-seq [20]) or oxidative bisulphite sequencing
(oxBS-seq [21]), with chemical modification-assisted
bisulphite sequencing (CAB-seq) developed for 5caC
[22], and reduced bisulphite sequencing (redBS-seq)
for 5foC [23]. Within the genome of mouse em-
bryonic stem (ES) cells, 5hmC has been found to be
enriched at promoters, especially those encoding bi-
valent chromatin domains and exons [24]. CpG islands
in mouse ES cells appear to be especially enriched for
5fC [25], but these studies used an affinity-based assay,
which may preferentially target such CG-rich loci [26].
Definitive nucleotide-resolution mapping studies will
undoubtedly be published in the near future, giving us
insights into the potential function of these cytosine
modifications.There have been numerous excellent reviews that have
described the panoply of DNA methylation assays cur-
rently available for use [19,28-31]. In this review, the
goal is to build upon this prior foundation with a focus
on the use of MPS technologies, especially as applied to
studying human diseases, including attention to the
study of cytosine variants other than 5mC, and incorpor-
ating a discussion about how new insights into genomic
Figure 2 The effects of bisulphite conversion on different cytosine variants. Bisulphite conversion deaminates not only unmodified cytosine
but also 5fC and 5caC [27] to uracil, which is then amplified and sequenced as a thymine. Both 5mC and 5hmC are resistant to bisulphite
conversion and are sequenced as cytosines. While the output of bisulphite sequencing has been generally described to be the ratio of 5mC/
(5mC + C), more correctly it should be described as (5mC + 5hmC)/(5mC + 5hmC + 5fC + 5caC + C), which only approximates 5mC/(5mC + C)
when the other cytosine variants are in very low proportions.
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to studying cytosine variants in the genome.
Review
Cytosine variants
To use the common terminology for mediators of epi-
genetic regulation, cytosine variants are established by
writers, bound to by readers, and removed by erasers.
Cytosine is the target of modifications in mamma-
lian genomes, the most common modification being
5-methylcytosine (5mC), usually at a cytosine followed
by a guanine, creating the CG (CpG) dinucleotide. The
CG dinucleotide combination is the shortest sequence at
which the opposite strand can have a complementary
cytosine within the dinucleotide, creating a palindromic
sequence. This allows a symmetrical modification of the
cytosines on both strands, which becomes important dur-
ing cell division when both of the daughter chromatids
form a hemimethylated state. The newly-synthesized
DNA has an unmodified cytosine that complements
the template strand with the 5mC. The recognition of
this hemimethylated state and the subsequent enzymaticrestoration of symmetrical 5mC on both strands represent
the best-characterized molecular mechanisms for herit-
ability of nongenetic information. As such, 5mC repre-
sents the one clearly epigenetic process in mammalian
genomes. The DNA methyltransferase enzyme involved
in restoring symmetrical DNA methylation following
replication is DNMT1 [32], whereas the DNMT3A and
DNMT3B enzymes can act upon nonreplicating DNA
to induce DNA methylation de novo [33]. The DNMTs
thus represent the writers of the 5mC state, with differ-
ent members of this protein family acting at different
stages of the cell cycle.
5-methylcytosine is now just one of several cytosine
modifications recognized to occur in mammalian DNA.
The relative abundance of each of the other variants is
substantially less, delaying their recognition and the devel-
opment of assays for their analysis. 5mC can be oxidized by
the TET family of enzymes to form 5-hydroxymethylcy-
tosine (5hmC), which is further oxidized by TETs to
5-formylcytosine (5fC) and to 5-carboxylcytosine (5caC)
[34]. These are believed to be steps involved in the active
transition from 5mC to unmodified cytosine. The TET
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state, but also as writers of the 5hmC, 5fC and 5caC states
(Figure 1).
The readers of 5mC are characterized by proteins
with methyl-binding domains (MBDs) and include the
MECP2 protein, which, when mutated, has been asso-
ciated with the development of Rett syndrome [35]
and autism spectrum disorder [36]. A relative preference
for 5hmC and 5fC compared to cytosine or with 5mC has
been identified for several DNA-binding proteins [37],
suggesting that these modifications are not merely transi-
ent stages in demethylation but have functional relevance
in transcriptional control. Some of the readers of 5mC
have been tested for their relative capacity to bind to
5hmC, with the MBD of MECP2 showing a strong prefer-
ence for 5mC over 5hmC [38]. The presence of 5mC at
certain sites inhibits the ability of certain transcription fac-
tors and DNA-binding proteins to bind to their cognate
motifs [39], so the absence of 5mC could, paradoxically,
be said to have its own readers. When 5mC is found at a
cis-regulatory element, it has usually been found to be
associated with the silencing of the associated gene [40],
leading to the cytosine modification being described as
repressive. As the majority of DNA in mammalian ge-
nomes is 5mC-modified [41], and cis-regulatory sites are
frequently characterized by their lack of 5mC [42-45], the
importance of 5mC may be mostly in terms of where it is
not located in the genome.
Pericentromeric regions of repetitive DNA are highly
enriched for 5mC through the action of DNMT3B [46]. Be-
tween this localization to cytogenetically heterochromatic
regions and the silencing effect of 5mC at cis-regulatory
loci, the assumption has been long held that more methyl-
ated cytosines define the more heterochromatic regions of
the genome. We have described the paradoxical finding
that the majority of the human genome is characterized by
enrichment of 5mC in the vicinity of regions with higher
levels of transcription, earlier DNA replication timing and
generally increased DNase hypersensitivity [47]. This target-
ing of 5mC to regions of euchromatin may be at least in
part attributable to the effect of transcription, which in-
duces the local accumulation of 5mC [48,49].
A consequence of 5mC is increased propensity to
mutations. When an unmodified cytosine undergoes
spontaneous deamination, it becomes a uracil, which
is readily recognized not to be part of the native DNA
sequence and is efficiently removed and repaired. The de-
amination of 5mC, on the other hand, generates thymine,
which could be native to the DNA sequence. The thymine
in the double-stranded DNA is mismatched with a guan-
ine downstream from a 5mC on the other strand, creating
a T:G mismatch and hemimethylated DNA that is specific-
ally recognized by MBD4 [50], a thymine DNA glycosylase
that removes the thymine for replacement by cytosine.This recognition and replacement must not be wholly
effective, as CGs dinucleotides are hotspots of DNA muta-
tions in somatic cells [51], and CGs are extremely depleted
in genomes of organisms that have 5mC [52,53]. The
depletion of CGs is not uniform in the genome, with a
subset of the genome remaining relatively CG-dense.
These regions of CG density have been described as CpG
islands [54] and have been the target of many studies of
DNA methylation, prompted by the observation that in
certain cancers these normally unmethylated loci can be-
come the target for acquisition of 5mC, which is referred
to as the CpG Island methylator phenotype (CIMP) [55].
The presence of 5mC at these loci in nonmalignant cells is
a rare event, including a small subset of canonical gene
promoters [56] as well as loci undergoing X chromosome
inactivation [57] and genomic imprinting [58]. CpG
islands are frequently located at gene promoters and tend
to be unmethylated in noncancerous cells whether the as-
sociated gene is active or inactive [59], generally providing
little predictive information about gene expression in pri-
mary, non-neoplastic cells. The CpG island annotation is
surprisingly simplistic, based on the observed to expected
ratio of CG dinucleotides and the (G + C) mononucleotide
proportion in windows of ≥200 bp [54]. When such se-
quences are annotated in the human genome, approxi-
mately 350,000 loci match these criteria, with 92% located
within repetitive elements. Those used for public genome
browser annotations start by removing the repetitive
sequences, focusing on the approximately 28,000 located
within unique sequence [60]. If the base composition
characteristics of CpG islands are functionally important,
it is difficult to rationalize why the removal of 92% of loci
with such characteristics is warranted. With the alterna-
tive hypothesis that the generally unmethylated status of
CpG islands is the more valuable annotation, an innova-
tive approach was employed that used the CXXC protein
domain, known to bind selectively to unmethylated CG
dinucleotides [61], to pull down ‘nonmethylated islands’
(NMIs) from DNA of multiple species. The authors
describe finding that while NMIs tend to be enriched for
the base compositional characteristics of CpG islands, the
property of being unmethylated is better than the CpG
island annotation at predicting regulatory elements in a
genome and is more conserved across genomes of differ-
ent species [62].
Our tradition of directing 5mC assays towards the
analysis of the CpG islands annotated in genome
browsers is therefore likely to be suboptimally inform-
ative when seeking to define loci where changes in 5mC
are associated with transcriptional changes. In fact, 5mC
changes flanking the CpG island itself have been found
to be more correlated with nearby gene transcriptional
levels than 5mC variability within the CpG island itself.
This so-called CpG island shore represents the 2 kb region
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lation associated with decreased gene expression levels
[63]. An insight into these CpG island shores comes from
our recent study of human CD34+ hematopoietic stem
and progenitor cells (HSPCs), which reveal these shores to
be highly enriched for sequences with the chromatin char-
acteristics of enhancers [64]. In now appears from exam-
ples in cancer [65], other human diseases [66-70] and
normal cells [42,71], that DNA methylation variability at
distal cis-regulatory loci such as enhancers is more corre-
lated with gene expression than DNA methylation at pro-
moters or CpG islands. Cis-regulatory loci now appear to
represent the most rewarding potential sites for 5mC
assays.
The reason for 5mC to exist in broad regions of the
mammalian genome, avoiding cis-regulatory elements,
has been the subject of speculation. It has been proposed
that 5mC exists to repress transposable elements (the
host defense hypothesis [72]), or to prevent activity of
cryptic promoters (transcriptional noise hypothesis [73]),
and that it is protective against chromosomal instability
[74]. Oddly, the times during mammalian development
when transposon activation or chromosomal rearrange-
ments could be most damaging probably include during
gametogenesis and early development, both character-
ized by profound demethylation throughout the genome
[75], with evidence for activation of transposable ele-
ments [76]. There is some published evidence to support
the transcriptional noise hypothesis [77]. The chromo-
somal instability hypothesis is mostly supported indir-
ectly by cytogenetic findings in DNMT3B deficiency
(ICF syndrome [46]), the increased rate of loss of hetero-
zygosity in tumors formed in mice with Dnmt1 muta-
tions [78] and the induction of fragile sites [79] and
chromosome breakage [80] by DNMT1 inhibitors. The
chromosome breakage may, however, be attributable to
adducts between the drug and DNMT1 and not the hy-
pomethylation of the DNA itself [81]. Overall, even after
decades of studies of 5mC physiology, the necessity for
it to be located throughout the mammalian genome re-
mains incompletely understood.
Current approaches to studying DNA methylation
changes in human diseases
The first insights into the potential role of DNA methy-
lation alterations in human diseases were from cancer
studies at individual loci, as described earlier. The extreme
changes of DNA methylation in cancer, with global shifts
and the unusual acquisition of DNA methylation at CpG
island promoters, established a paradigm for the study of
other diseases. The range of human diseases and pheno-
types being studied is now extremely broad, including
aging [82], immunological [83], renal [66], neurological
[84], pulmonary [85], gastrointestinal [86], infectious [87]and other diseases. The same extreme changes are rarely
seen in these nonmalignant conditions, with the exception
of certain viral infections [88]. Another common finding
is that the loci that change DNA methylation almost never
do so in a way that involves switching between extreme
hypomethylation to extreme methylation. Instead, the
changes seem to be intermediate in degree with values as
low as a few percent distinguishing the groups.
The observation of small changes in methylation be-
tween groups has three practical implications. First, it
indicates that the changes in DNA methylation occur in
a subset of the pool of cells sampled. An individual cell
cannot have an intermediate DNA methylation value
such as 20%: either both cytosines are methylated on the
homologous chromosomes (100%), neither is methylated
(0%), or in certain situations there is 50% DNA methyla-
tion when one but not the other allele is methylated. A
change of DNA methylation from 20% to 40% between
samples means that there has to be a mosaic subpopula-
tion of alleles or cells that changes its proportion. This
raises the question of whether the effects are purely due
to differences in cell subcomposition between the sam-
ples. This has retrospectively been found to be the case
in a number of studies of aging using peripheral blood
leukocytes [89]. Re-analysis of these samples, using DNA
methylation patterns known to characterize individual
leukocyte subtypes to deconvolve the global patterns
observed, revealed that the effects of aging were almost
wholly attributable to cell subtype composition, and
may not reflect epigenetic changes in any of the cells
studied [89].
The second consequence of intermediate DNA methy-
lation changes occurring in human disease studies is that
it puts pressure on the genome-wide assay to be capable
of detecting small changes. It has been proposed that
the kind of deconvolution approach used to understand
the effects of cell subcomposition in aging [89] can be
applied analytically to remove this confounding effect
and allow genuine epigenetic changes to be detected
[90]. This is a reasonable assumption and has potential
to rescue studies that are based on the use of mixed cell
types. What remains problematic is the possibility that
the epigenetic changes may only be occurring in a pro-
portion of a subtype of the cells studied. Even purified
cells have been found to show intermediate changes in
DNA methylation in these kinds of studies [91-93], rais-
ing the possibility that if a cell subtype undergoing the
epigenetic change represents, for example, 10% of the
mixed population of cells being studied, and the DNA
methylation changes associated with the disease are in
the range of 20% in that affected cell subtype but no
other cells in the population change their DNA methy-
lation, the genome-wide assay has to detect (0.10 ×
0.20) a 2% change in DNA methylation in the mixed cell
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does not have sufficient resolution or sensitivity to de-
tect changes of such limited magnitude.
The third problem is not immediately intuitive, and
represents an indirect implication of mosaic epigenetic
events. A question that frequently arises is whether
chromatin immunoprecipitation (ChIP)-based studies
can be used in human diseases, instead of the common
approach of studying DNA methylation. ChIP followed
by MPS (ChIP-seq [94]) is the genome-wide assay that
allows us to map chromatin components such as post-
translational histone modifications, DNA-binding pro-
teins and chromatin structure. The assay results in a
binary peak/no peak output, and while there has been
some progress making the assay more quantitative [95],
it is not yet an assay that allows the distinction between,
for example, a sample in which 20% of the cells have
trimethylation of lysine 4 in histone H3 (H3K4me3) and
another sample in which the proportion of cells with
H3K4me3 is 40%. More development of ChIP-seq is
needed before it will be capable of detecting the epigen-
etic changes that appear to characterize human diseases.
While it would be of immense value to be able to add
studies of other transcriptional regulatory processes in
human diseases using quantitative ChIP-seq, at present
our focus in human disease studies remains limited to
the study of DNA methylation.
Global DNA methylation assays
A first step in many human disease studies of DNA
methylation is the quantification of global DNA methy-
lation levels, prompted by the observed global shifts in
DNA methylation that characterize certain tumors [96]
and have also been found to occur in certain viral infec-
tions [88]. Highly quantitative tests for all cytosines in
the genome include mass spectrometry [97] and high-
performance liquid chromatography [2], which would
also generate information about cytosine variants other
than 5mC, but which both require specialized equip-
ment and expertise that are not universally available. Py-
rosequencing [98] also requires specific equipment and
has been used to quantify the C/T ratio in bisulphite-
converted DNA to measure DNA methylation at specific
loci [99]. By targeting the highly repetitive L1 LINE
(LINE1) and Alu SINE sequences, an estimate of global
DNA methylation can be acquired. It should be noted
that this represents types of sequences in the genome
that are normally highly methylated [100], so the test is
more sensitive to a global loss of DNA methylation than
its global acquisition. The luminometric methylation
assay (LUMA) also uses pyrosequencing but is preceded
by restriction enzyme (RE) digestion of the genomic
DNA, measuring the quantity of overhanging ends of
fragments digested by methylation-sensitive REs (forexample, HpaII), normalized to digestion by a methylation-
insensitive isoschizomer (for example, MspI) and controls
for restriction enzyme digestion (for example, EcoRI) [101].
HpaII and MspI represent about 8% of CGs in the genome
[102] and are present in both methylated and unmethylated
contexts, allowing LUMA to report global shifts in DNA
methylation that can also be from less to more methylated
states. An excellent recent review compares these global
DNA methylation quantification approaches [103], with the
development of a new mass spectroscopy-based isotope tra-
cing technique reported more recently [104] that demon-
strates the additional ability to test the dynamics of these
modified cytosines in living cells.
From microarrays to massively parallel sequencing
Of the assays used for genome-wide DNA methylation
studies in human diseases, microarrays currently appear
to be the most widely used [105]. This reflects some of the
pragmatic choices that have to be made by an investigator
when choosing how to perform a maximally informative
study of a human disease phenotype. We have described
earlier why DNA methylation represents a better choice at
present than ChIP-seq for epigenomic and transcriptional
regulatory studies; the choice within DNA methylation
assays then bifurcates into a microarray or MPS-based
approach. It should be noted that microarrays and MPS
merely map and quantify the results after a pre-treatment
of the DNA. This pre-treatment can be affinity-based,
selective enriching methylated [106] or unmethylated
[107] DNA. The pretreatment can also be based on the
use of methylation-sensitive restriction enzymes [108] or
bisulphite conversion of DNA [109]. Of these, the
commonly-accepted gold standard approach is shotgun
whole-genome bisulphite sequencing (WGBS), which gen-
erates nucleotide-resolution, quantitative information at
most cytosines throughout the genome. It remains, how-
ever, a very expensive assay to perform, prompting the de-
velopment of what could be called ‘survey’ assays that test
a subset of the cytosines dispersed throughout the gen-
ome. The oligonucleotides on microarrays have tradition-
ally been designed to represent the sites believed by
researchers to be informative locations for DNA me-
thylation changes, usually enriching representations at
annotated promoters, CpG islands and their shores, and
loci such as imprinted differentially-methylated regions
(DMRs) [110,111]. Survey approaches using MPS divide
into two groups, the reduced representation bisulphite
sequencing (RRBS) approach that uses a size range of
fragments generated by RE digestion to target deep
sequencing to these specific loci [111], and assays that
use methylation-sensitive RE digestion to generate tags
at these sites, proportionally representing the degree of
DNA methylation at those sites, exemplified by our
HELP-tagging assay [108].
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data correlate well with WGBS [112,113]. Approaches
involving MPS generate information not possible from mi-
croarrays, including SNP detection [108,114] and DNA
methylation entropy [115,116]. Microarrays are generally
designed with the assumption that 5mC occurs only in
the context of CG dinucleotides, but in certain human cell
types, there are detectable levels of CHG and CHH methy-
lation [41], which would either not be detected or would
introduce unexpected effects, for example interfering with
digestion by the normally DNA methylation-insensitive
MspI [117]. As mentioned earlier, CG dinucleotides are
very mutable and polymorphic, which is a problem for
microarray designs that include a substantial component of
CGs that represent known common SNPs [118,119].
The substantial advantages to MPS in general and
bisulphite sequencing in particular are becoming in-
creasingly apparent.
It should however be recognized that bisulphite se-
quencing represents different cytosine modifications in
distinctive ways (Figure 2). The unconverted cytosine
output of bisulphite sequencing should not be taken to
represent merely 5mC but also the contribution of
5hmC at that site. To resolve the relative proportions of
each, both a bisulphite (5(h)mC) and a specific 5hmC
assay need to be performed in parallel. Both 5fC and
5caC are read by bisulphite conversion as unmodified
cytosines, requiring their specific detection using further
specialized assays. The range of assays available to detect
multiple cytosine variants was extensively reviewed re-
cently [19]. The low relative proportions of 5hmC, 5fC
and 5caC make their quantification by sequencing even
more challenging than for 5mC, requiring a substantially
deeper representation of the genome to detect alleles oc-
curring at low frequencies. This increases the relative
costs associated with these assays.
All of the prior discussion of MPS has implied the use of
technologies based upon sequencing by synthesis, exempli-
fied by the Illumina platform, indirectly measuring cytosine
modifications following their chemical conversion and
PCR amplification. It should, however, be noted that there
are MPS platforms that use the primary DNA sequence ra-
ther than amplified derivative material, and obtain qualita-
tive data about the sequence that appear to reflect DNA
methylation, for example, the SMRT sequencing approach
from Pacific Biosciences [120]. The throughput of this plat-
form currently precludes it being able to study genomes
the sizes of those of mammals, but SMRT sequencing or
nanopore approaches [121-123] may over time become
alternatives to the indirect approaches currently used.
Biases and verification
All genome-wide assays studying DNA methylation have
inherent biases. Some are designed intentionally, such asthe choice of oligonucleotides in microarrays, or the
choice of restriction enzymes in other assays, with RRBS
intentionally using short MspI fragments to target CG-
dense regions, for example. Affinity-based pulldown
approaches have long been appreciated to have depend-
ence on the density of potential targets in the genome
[124-126]. Even the gold standard approach of bisulphite
conversion is associated with a bias involving strand speci-
ficity of sequence reads [127,128], leading to the expect-
ation that all of the newer assays for other cytosine
variants will eventually be found to have their own sys-
tematic sources of error.
It is therefore essential to verify results obtained using
genome-wide assays with more quantitative, targeted
studies of individual loci, if possible using orthogonal
assays. For DNA methylation, a genome-wide assay using
microarrays or a restriction enzyme-based MPS assay
should be tested using bisulphite sequencing at a number
of individual loci, together representing the range of va-
lues obtained in the genome-wide approach, with a focus
on any DMRs observed. Assays that allow relative single
nucleotide polymorphism (SNP) proportions to be mea-
sured such as pyrosequencing (Qiagen) or MassArray
(Sequenom) would be suitable means of testing amplicons
from bisulphite-converted DNA.
Some genome-wide DNA methylation assays do not
test individual nucleotides but are instead dependent
upon the DNA methylation state of multiple cytosines in
a region. Affinity-based assays are the best known ex-
ample of this kind of dependence, but low coverage
bisulphite sequencing followed by the BSmooth analyt-
ical approach [129] or the output of Bumphunter [130]
are other examples. If the assay is regionally-based in-
stead of nucleotide-based, the verification should test
the cytosines throughout the region implicated to have
distinctive DNA methylation, as a single cytosine may
not fully represent the DNA methylation of the locus as
a whole.
If SNPs (or other genomic sequence variants) are not
detected in the genome-wide assay, especially if a DMR
is located at a site of a known SNP, it becomes important
to test whether the results reflect the presence of a se-
quence variant. SNPs causing effects on DNA methylation
assays can be categorized into two groups: those imme-
diately at the cytosine being tested, and those located at
a distance that can affect DNA methylation at the site
tested, so-called methylation quantitative trait loci
(mQTLs) [131]. While the former category is relatively
straightforward to identify, mQTLs can be located tens
of kilobases from the site at which they affect DNA
methylation [132,133], which creates a major challenge
in trying to understand whether differential DNA methy-
lation is due to DNA sequence variability or an independ-
ent epigenetic event. We have shown that SNP genotyping
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for the effect of ancestry upon DNA methylation variabil-
ity [92], which is a relatively cost-effective strategy, but
our expectation is that DNA methylation studies will need
to include genomic sequencing in parallel if we are to
account fully for mQTL influences, which have been esti-
mated to account for 22 to 80% of variability on DNA
methylation between individuals [132,133].
Human disease studies and cis-regulatory regions
Human disease studies have to be designed with the
assumption that the DNA methylation changes will be
modest, in a group of individuals who may be heteroge-
neous in their epigenetic associations with the pheno-
type, and subject to confounding variables such as cell
subpopulation variability and mQTLs influencing results.
To design this kind of study properly requires reduction
of the effects of known confounding variables to the
greatest extent possible, but will also probably require
cohorts of sizes larger than studied to date [105].
This impacts the choice of DNA methylation assay.
Ideally, we would use the most comprehensive and
quantitative assay available, WGBS. If the cell type were
found through a global assay to contain reasonably sub-
stantial amounts of 5hmC, adding this information would
help to discriminate the 5mC and 5hmC contributions to
specific loci. Unfortunately, the cost associated with
WGBS on its own is currently at least several thousand
US dollars, and, as mentioned above, the depth of sequen-
cing required for quantification of the less abundant
5hmC modification would need to be even greater, with
associated costs.
It is therefore understandable that researchers have
opted to use survey approaches in human disease studies.
Important factors in the use of these assays for human dis-
ease studies should include ease of use, as the assay may
need to be used repeatedly as samples are acquired over
time, so a reproducible workflow is essential. The assay
should be able to use limited sample quantities, which is
often an issue with material from clinical sources, espe-
cially if cell purification is performed. Microbial contamin-
ation is inherent to certain types of epithelial samples,
which would represent a potential problem in shotgun
sequencing-based approaches.
A major current concern is that the survey approaches
should be testing the most informative regions of the
genome. The assumption to date has been that the target-
ing of promoters and CpG islands optimizes the infor-
mation available from these assays, but as described
earlier, the dynamic changes in DNA methylation that
are associated with transcriptional changes appear to
occur more frequently at nonpromoter cis-regulatory
elements [42,65-71] and at CpG island shores [63], where
enhancers appear to be enriched [64]. Adding in CpGislands allows the further identification of DNA methyla-
tion acquisition at these elements in the more extreme
epigenetic dysregulation occurring in cancer [55].
Human diseases are increasingly recognized to be
associated with DNA methylation changes at cis-regula-
tory loci other than promoters. This is now being identi-
fied in cancer [65,68-70] and noncancerous conditions
[66,67] as well as normal cell differentiation [71]. An
obvious question that arises is whether current, com-
monly used DNA methylation assays represent these
nonpromoter cis-regulatory elements adequately. Map-
ping cis-regulatory loci has been facilitated by ChIP-seq
assays, with the ENCODE project using combinations of
mapped chromatin states to define different functional
properties of the genome, including enhancer and in-
sulator functions [134]. To test how well several assay
types represent different genomic properties, we used
published WGBS and RRBS data [112], the list of loci
represented by the Illumina Infinium HumanMethyla-
tion450 microarray [110] and the HpaII loci repre-
sented by the HELP-tagging assay [108]. We used the
features generated by ChromHMM [135] and Segway
[136] analyses of human embryonic stem cells avail-
able from the ENCODE group [137] as a source of
annotations of functional elements in a reference cell
type. We then measured the proportion of loci in each
type of annotation overlapped by one or more loci inter-
rogated by an assay. For example, if a type of feature is
predicted by ChromHMM to occur in the genome 100
times, and the Illumina 450 K microarray has one or
more probes at 50 of these genomic locations, the fea-
ture would be said to be represented 50% of the time by
the microarray assay.
We show the results of this analysis in Figure 3. As
can be seen, WGBS is the best at representing cis-regula-
tory sequences (promoters and enhancers), with approxi-
mately 55 to 90% of these individual features represented,
but also includes substantial representation at the less
informative transcribed and heterochromatic loci. All of
the survey assays are at their best representing pro-
moters, but the assays all have in common that they
only report a minority of the candidate cis-regulatory
sequences predicted by Segway and ChromHMM. These
results have to be interpreted with appropriate caution -
deeper sequencing would increase the representation by
WGBS and RRBS, as should the use of the enhanced
RRBS technique [138], but it is not expected that any such
measure will address the fundamental problem that the
majority of the loci that are most likely to be informative
are not tested by anything except the costly WGBS ap-
proach. Furthermore, as enhancers are highly cell type-
specific [139], no single design for a survey assay is likely
to be informative across all cell types tested in human dis-
ease studies.
Figure 3 The proportional representation of functional genomic elements by different DNA methylation assays. Using annotations of
human embryonic stem cells by Segway (a) and ChromHMM (b), we calculated how four types of genome-wide DNA methylation assays represent
each type of functional element. When the proportion of functional genomic elements tested by each assay is calculated, all of the assays work best
to represent the candidate promoters annotated by Segway (a) or ChromHMM (b), but generally only represent a minority of candidate cis-regulatory
elements. Even WGBS does not represent 100% of each functional genomic element, so no assay achieves complete comprehensiveness, and the
penalty of the WGBS approach is that it sequences equally deeply a number of genomic contexts that are not as likely to be informative, an inefficient
use of costly sequencing resources.
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The focus therefore turns to how we can perform targeted
bisulphite sequencing. This can be performed using multi-
plexed PCR for relatively limited representations of the
genome [140] or padlock probes [141]. For more extensive
genomic coverage, two types of capture-based assays have
been described, those involving capturing DNA at target
regions and then converting it using bisulphite treatment
[142], and the opposite, converting with bisulphite and
then capturing [143], proceeding to sequencing the
enriched subset of the genome in both cases. The former
approach is commercialized by Agilent as MethylSeq, the
latter by Roche-NimbleGen as SeqCap Epi. Each should
allow a targeting of loci in a cell type-specific manner,
using enhancer predictions from the ENCODE or Road-
map in Epigenomics programs or from an investigator’sown ChIP-seq characterization of that cell type. As the
enhancer landscape is much more variable between cell
types than for promoters [139], a necessary component of
this approach is the development of cell type-specific tar-
geting design. The observation that hypomethylation of
DNA at cis-regulatory loci can expand and contract sug-
gests that the most informative sites within these loci may
be those at the edges of the individual cis-regulatory locus
[4]. With capture involved, any DNA from microbial
contamination should be depleted, making it suitable for a
broader range of human specimens. These capture ap-
proaches involve bisulphite sequencing, allowing the
qualitative advantages of bisulphite reads to be exploited,
including SNP detection, DNA methylation entropy infor-
mation, and non-CG methylation. It is also reasonable to
assume that a capture approach that works for bisulphite-
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that look for other cytosine variants (Figure 4), allowing
deep sequencing and more accurate and sensitive detec-
tion of these variants as a result. At present, the most
promising survey approach for DNA methylation studies
in human disease would appear to be a capture-based sys-
tem targeting cis-regulatory loci in the cell type of interest.
Conclusions
DNA methylation has been studied for decades but it
still only slowly revealing its normal physiological roles
and its patterns of associations with human diseases and
other phenotypes. Studies of DNA methylation remain
the foundation for human disease studies, revealing not
only genuine epigenetic associations but also insights
into cell subtype and DNA polymorphism differences
characterizing the individuals with diseases. We are
moving increasingly towards the adoption of bisulphite
sequencing-based approaches to interrogate DNA methyla-
tion, but are beginning to appreciate that we may need to
enrich the assay’s representation of nonpromoter cis-regula-
tory sequences. As these cis-regulatory sites will differ sub-
stantially between cell types, we have to reconsider the idea
that a single assay design will be able to serve all studies,
and that instead we need to develop cell type-specific assay
designs. At present, the capture-based assays appear to beFigure 4 Assays for cytosine modifications and a targeted sequencing
both 5mC and 5hmC, and two assays detecting 5hmC alone, as examples
that captures bisulphite converted DNA can be used downstream of these
interest, here indicated by cis-regulatory elements (a). In (b) we show the step
TAB-seq and oxBS-seq.best positioned to allow this kind of targeted bisulphite se-
quencing, with the potential for these assays also allowing
targeted studies of cytosine variants other than 5mC.
Methods












Annotated HpaII sites in hg19 assembly
ChromHMM/Segway annotations of H1 ES cells:
http://ftp.ebi.ac.uk/pub/databases/ensembl/encode/
integration_data_jan2011/byDataType/segmentations/
jan2011/ (available as Guest login).
Description of how annotations were generated:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553955/
bin/supp_41_2_827_v2_index.htmlstrategy. We show regular bisulphite sequencing, which reports
of the broader group of assays detecting cytosine variants. Any system
sample preparation approaches to target deep sequencing to loci of
s and the nucleotide conversions involved in bisulphite sequencing,
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